Financial writer recommends Crispr Therapeutics AG as a strong buy due to cash position, drug pipeline, and promising ...
H.C. Wainwright analyst Mitchell Kapoor initiated coverage of Crispr Therapeutics (CRSP) with a Buy rating and $65 price target The firm says ...
Hosted on MSN3d
HC Wainwright & Co. Initiates Coverage of CRISPR Therapeutics (CRSP) with Buy RecommendationFintel reports that on February 3, 2025, HC Wainwright & Co. initiated coverage of CRISPR Therapeutics (NasdaqGM:CRSP) with a ...
In the latest trading session, CRISPR Therapeutics AG (CRSP) closed at $40.49, marking a +1.23% move from the previous day. The stock's change was more than the S&P 500's daily gain of 0.72%. On the ...
The Motley Fool on MSN21d
2 Magnificent Stocks to Buy That Are Near Their 52-Week LowsSome investors believe you make money when you buy a stock, not when you sell it ... provided there are good reasons to believe it will bounce back. CRISPR Therapeutics is a mid-stage biotech ...
DeepSeek was tasked with selecting two stocks investors can buy now and hold long-term due to their growth potential.
The bottom line is few companies can match its combination of established leadership in rare diseases and realistic pathways ...
Analyst Gil Blum from Needham maintained a Buy rating on Crispr Therapeutics AG (CRSP – Research Report) and keeping the price target at $84.00. Discover outperforming stocks and invest smarter ...
Results that may be inaccessible to you are currently showing.
Hide inaccessible results
Feedback